Neurometabolites and Antipsychotic Response in Psychosis: A Mega-Analysis.

JAMA PsychiatrySep 1, 2026
Clinical ResearchPsychiatryOpen access

Bridget King, Kirsten Borup Bojesen, Charlotte Crisp et al.

✦ AI-curated · Sources linked

In 30 seconds

This meta-analysis examined neurometabolite differences in antipsychotic nonresponders versus responders in psychosis, analyzing data from 1189 participants across 18 studies. Nonresponders exhibited significant elevations in medial frontal glutamate (Glass g=0.21; P=0.02), glutamate plus glutamine (g=0.29; P=0.002), choline (g=0.22; P=0.03), and myo-inositol (g=0.35; P=0.001) compared to responders.

Key findings

  • Nonresponders showed elevated medial frontal glutamate (Glass g=0.21; P=0.02) compared to responders.
  • Elevated glutamate plus glutamine in nonresponders was observed prospectively in first-episode psychosis (g=0.41; P=0.002).
  • Myo-inositol elevations were greatest in treatment-resistant individuals (Glass g=0.64; P=0.001).
  • The meta-analysis revealed elevated medial frontal choline and myo-inositol in nonresponders.

Why it matters

Identifying neurobiological markers associated with antipsychotic nonresponse can enhance outcome prediction and guide the development of targeted treatments for psychosis, potentially improving patient management.

Source

PubMed · PMID 42340705Free full text on PubMed Central

Published in JAMA Psychiatry. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchOncology (Medical)

Osimertinib With or Without Chemotherapy in Advanced Non-Small Cell Lung Cancer With EGFR and Concurrent TP53 Mutations: A Randomized Clinical Trial.

This phase 3 randomized clinical trial evaluated the efficacy and safety of osimertinib combined with chemotherapy versus osimertinib alone in 294 patients with advanced non-small cell lung cancer (NSCLC) harboring…

JAMASep 8, 2026Open accessRead summary
Clinical ResearchHematology

Azacitidine-Venetoclax or Induction Chemotherapy for Acute Myeloid Leukemia.

This phase 2 randomized trial compared azacitidine plus venetoclax to induction chemotherapy in 172 previously untreated adults with acute myeloid leukemia (AML) eligible for induction.

N Engl J MedSep 3, 2026Read summary
Clinical ResearchPsychiatry

The efficacy of modified psychodynamic psychotherapy for patients with schizophrenia-spectrum disorders in Germany: a prospective, single-centre, assessor-blinded, parallel-group, randomised controlled trial.

This randomized controlled trial evaluated the efficacy of Modified Psychodynamic Psychotherapy for Schizophrenia (MPP-S) combined with treatment as usual (TAU) in 130 outpatients with schizophrenia-spectrum disorders…

Lancet PsychiatrySep 10, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.